Accel Pharma reports upcoming two-week shortage of ondansetron 4 mg tablets
Accel Pharma reports its ondansetron orally-disintegrating tablet 4 mg (ACCEL-ONDANSETRON ODT, DIN 02535319) faces an anticipated shortage from Nov 1 to Nov 15, 2026, caused by a shortage of an active ingredient.
Ondansetron is a widely used anti-nausea drug — pharmacies should check stock and alternatives before the anticipated shortage starts Nov 1.
Shortage expected to end: Nov 15, 2026 Gach ceann-latha
Faighnich mun gheàrr-chunntas seo
Tha freagairtean air an sgrìobhadh le AI bhon gheàrr-chunntas seo agus dh'fhaodadh iad a bhith ceàrr. Thoir sùil air an tùs thùsail mus dèan thu dad.
2 cheist an-asgaidh gach latha às aonais cunntas. Faodaidh buill faighneachd cho tric 's a thogras iad, an-asgaidh.
Chan e comhairle mheidigeach, laghail no in-imrich a tha seo. Thèid ceistean a chumail gun urra gus ar geàrr-chunntasan a leasachadh.
Leugh an tùs
Tùs oifigeil: Accel Pharma reports upcoming two-week shortage of ondansetron 4 mg tablets (a' fosgladh ann an taba ùr) — Health Product Shortages Canada